Truist Securities Maintains Hold on AnaptysBio, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst John Lee maintains a Hold rating on AnaptysBio (NASDAQ:ANAB) and raises the price target from $20 to $30.
August 15, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst John Lee maintains a Hold rating on AnaptysBio and raises the price target from $20 to $30.
The raised price target from $20 to $30 by Truist Securities is a positive signal for AnaptysBio, indicating improved expectations for the company's stock performance. However, the Hold rating suggests a neutral stance, balancing the positive impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100